

Date of the CVA	31/05/2021
-----------------	------------

## Section A. PERSONAL DATA

Name and Surname	Carlos Ferrer Albiach		
DNI	22.678.710 C	Age	61
Researcher's identification number	Researcher ID		
	Scopus Author ID		
	ORCID	0000-0001-9122-7646	

\* Obligatorio

### A.1. Current professional situation

Institution	Ministry of Health, Consumer Affairs and Social Welfare		
Dpt. / Centre			
Address	ramon y cajal 33-12, 46007, Valencia		
Phone	(+34) 964354386	Email	<a href="mailto:ferreralbiach@gmail.com">ferreralbiach@gmail.com</a>
Professional category	Member of the National Commission of the Speciality of Radiation Oncology	Start date	2019
Keywords			

### A.2. Academic education (Degrees, institutions, dates)

Bachelor/Master/PhD	University	Year
Expert in Health Management	Menendez y Pelayo International University	2020
Titulo de Doctor en Medicina, Facultad de Medicina	Universitat de València	1995
Licencia de Supervisor de instalaciones radiactivas	Consejo de Seguridad Nuclear	1994
Medico Especialista en Oncología Radioterápica		1992
Grado de Licenciatura		1986
Licenciado en Medicina y Cirugía	Facultad de Medicina, Universidad de Valencia	1984

### A.3. General quality indicators of scientific production

## Section B. SUMMARY OF THE CURRICULUM

### Section C. MOST RELEVANT MERITS (ordered by typology)

#### C.1. Publications

AC: Autor de correspondencia; (nº x / nº y): posición firma solicitante / total autores

- 1 Scientific paper.** Falk Roeder; Carlos Ferrer Albiach; Felipe Calvo Manuel; Philip Poortmans; Virginia Morillo Macias. (3/5). 2020. Intraoperative radiation therapy (IORT) for soft tissue sarcoma - ESTRO IORT Task Force/ACROP recommendations RADIOTHERAPY AND ONCOLOGY. Elsevier. 150, pp.293-302.
- 2 Scientific paper.** Jose Pardo Masferrer; Carlos Prieto Martin; Carlos Ferrer Albiach. (3/3). 2020. Safety in radiation oncology: transposition of directive 2013/59/EURATOM in the Spanish Radiation Oncology Departments-recommendations for its adequate and effective application Clinical and Translational Oncology. Springer. 22, pp.2097-2102.
- 3 Scientific paper.** Rades D; Hansen O; Jensen LH; et al; Ferrer-Albiach C; Holländer NH. (15/21). 2019. Radiotherapy for metastatic spinal cord compression with increased radiation doses (RAMSES-01): a prospective multicenter study British Medical Cancer. Biomedcentral. 10.1186/s12885-019-6.

- 4 **Scientific paper.** Rades D; Šegedin B; Conde-Moreno AJ; et al; Ferrer-Albiach C; Schild SE. (4/11). 2019. Patient-Reported Outcomes-Secondary Analysis of the SCORE-2 Trial Comparing 4 Gy × 5 to 3 Gy × 10 for Metastatic Epidural Spinal Cord Compression International journal of radiation oncology, biology, physics. Elsevier. 105-4, pp.760-764.
- 5 **Scientific paper.** Carlos Ferrer Albiach; Enrique Ochoa Aranda; Alfonso Gomez Iturriaga-Piña; et al; Francisco Garcia Piñón. (1/13). 2019. MicroRNA95 May Be Involved in Oligometastatic Prostate Cancer Journal of Cancer treatment and Research. Sciece PG. 7-2, pp.33-40.
- 6 **Scientific paper.** Pardo Masferrer J; Del Cerro Peñalver E; Contreras Martinez J; Ferrer Albiach C (AC); Patient Safety and Quality Working Group of the Spanish Society of Radiation Oncology (SEOR). (4/5). 2019. Patient safety in radiation oncology in Spain: a need to change.Clinical and translational Oncology. Springer. 10.1007/s12094-019-0.
- 7 **Scientific paper.** Ferrer Albiach C (AC); Villegas Estévez F; López Alarcón MD; et al; Sanz Yagüe A. (1/9). 2019. Real-life management of patients with breakthrough cancer pain caused by bone metastases in Spain Journal of Pain Research. Doce Press. 12, pp.2125-2135.
- 8 **Scientific paper.** Smith MR; Saad F; Chowdhury S; et al; SPARTAN Investigators;. (19/19). 2018. Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer N Engl J Med.
- 9 **Scientific paper.** Lara PC; Rodríguez A; Ferrer C; et al;. (3/8). 2018. Rescuing Spanish Radiation Therapy: The Role of Leadership and Opportunity Int. J. Radiat Oncol Biol Phys. 100-2, pp.292-296.
- 10 **Scientific paper.** López-Tarjuelo J; Bouché-Babiloni A; Morillo-Macías V; Santos-Serra A; Ferrer-Albiach C. (5/5). 2017. Practical issues regarding angular and energy response in in vivo intraoperative electron radiotherapy dosimetry.Reports of Practical Oncology & Radiotherapy. 22-1, pp.55-67.
- 11 **Scientific paper.** Vera R; Ferrández A; Ferrer CJ; et al;. (3/13). 2017. Procedures and recommended times in the care process of the patient with pancreatic cancer: PAN-TIME consensus between scientific societies Clin Transl Oncol. 19-7.
- 12 **Scientific paper.** Henríquez I; Bejar A; Maldonado X; et al; Ferrer C. (13/13). 2016. Intermittent versus continuous androgen deprivation therapy to biochemical recurrence after external beam radiotherapy: a phase 3 GICOR study Clinical and Translational Oncology.
- 13 **Scientific paper.** ; ; ; et al;. 2013. Clinical significance of VEGFR-2 and (18)F-FDG PET/CT SUVmax pretreatment score in predicting the long-term outcome of patients with locally advanced rectal cancer treated with neoadjuvant therapy.Department of Oncology, Hospital General Universitario Gregorio Marañón, Madrid, Spain, Eur J. Nuclear Med DOI:10.1007/s00259-013-2479-7.
- 14 **Scientific paper.** ; ; ; et al;. 2013. Research opportunities in intraoperative radiation therapy: the next decade 2013-2023 Clin Transl Oncol.
- 15 **Scientific book or monograph.** Ferrer C (AC). (1/1). 2020. Safety and Quality in Radiation Oncology 2nd Edition Role of the head of the radiation oncology department in the creation of a safety culture.EMIRAL editions. pp.74-77.
- 16 **Scientific book or monograph.** Carlos Ferrer Albiach. 2019. Seguridad y Calidad en Oncología Radioterápica Seguridad y Calidad en Oncología Radioterápica. Emiral ediciones. ISBN 978-84-09-11598.

## C.2. Participation in R&D and Innovation projects

- 1 MYC alterations in localised and advanced prostate cancer: clinical and molecular implications PI20/01642 David Lorente Estelles. (Castellón Provincial Hospital Consortium). 01/01/2021-31/12/2023. 87.120 €.
- 2 Prospective registry of hypofractionation confotontherapy and proton therapy with overprinting in Ga-PSMA-positive area in salvage after prostatectomy PI20/01598 Mauricio Cambeiro Vazquez. (Navarra University Clinic). 01/01/2021-31/12/2023. 68.970 €.
- 3 SBRT in oligometastatic prostate cancer.ClinicalTrials.gov Identifier: NCT02192788 Carlos Ferrer Albiach. (Castellón Provincial Hospital Foundation). 2017-2019. 3.000 €.

- 4 Sistema de Teleguiado Planificación y Automatización Prerobotizada de Tratamientos de Radioterapia Intraoperatoria Carlos Ferrer Albiach. (Instituto Salud Carlos III). 2012-2013. 93.000 €.
- 5 Subproyecto nº S-2: ALGORITMOS DOSIMETRIA IN-VIVO. Carlos Ferrer Albiach. (Ministerio de Ciencia e Innovación Convocatoria de proyectos singulares). 2009-2010. 50.602 €.
- 6 Subproyecto nº S-6 : FOMENTO DE LAS TECNOLOGÍAS PARA LA SEGURIDAD DEL PACIENTE Carlos Ferrer Albiach. (Ministerio de Ciencia e Innovación Convocatoria de proyectos singulares). 2009-2010. 5.323 €.
- 7 Técnicas de análisis de imagen aplicadas al control de calidad en radioterapia Carlos Ferrer Albiach. (Ministerio de ciencia y tecnología). 2003-2006.
- 8 Ensayo clínico ATLAS:” A randomized double blind Placebo controlled Phase III Study of JNJ-56021927 in subjects with High risk localized or locally advanced prostate cancer receiving treatment with primary radiation therapy. Protocol 56021927PCR3003 Carlos Ferrer Albiach. From 2015.
- 9 ensayo clínico SPARTAN “A multicenter, randomized, double-blind, placebo-controlled, phase III study of ARN-509 in men with non-metastatic castration-resistant prostate cancer The SPARTAN Study (Selective Prostate AR Targeting with ArN-509 Carlos Ferrer Albiach. From 2014.
- 10 Estudio multi-hospital de sistemas de simulación y entrenamiento en la optimización de la práctica clínica en Radioterapia intraoperatoria.Subprograma Proyectos de Investigación en Tecnologías Sanitarias y Servicios de Salud Carlos Ferrer Albiach. (Instituto de Salud Carlos III). From 2010.
- 11 Simulación y tratamiento guiado por la imagen en radioterapia Carlos Ferrer Albiach. (Ministerio de Ciencia e Innovación Convocatoria de proyectos singulares). From 2010.
- 12 Evaluación de la viabilidad y utilidad clínica de una herramienta de planificación y simulación de radioterapia intraoperatoria Carlos Ferrer Albiach. (FISS-ETES). From 2008.
- 13 ABVD versus NOPP con radioterapia en campo afecto en estadios I y II de la enfermedad de Hodgkin GRUPO PETHEMA (GRUPO PETHEMA). From 1995.

### **C.3. Participation in R&D and Innovation contracts**

### **C.4. Patents**